Optimeos Life Sciences
Optimeos is a company developing a novel nanoparticle platform for the intracellular delivery of RNA and DNA medicines. Their technology aims to improve the efficacy, safety, and targeting of RNA and DNA therapies, with applications in disease treatment and vaccine development. The company is led by a team of experts and actively seeks collaborations with biopharmaceutical companies to advance its innovative platform.
Industries
Nr. of Employees
small (1-50)
Optimeos Life Sciences
Products
Nanoparticle delivery platform for RNA and DNA therapeutics
A platform for intracellular delivery of RNA and DNA that supports tunable immunogenicity, co-encapsulation of multiple payload types, modular targeting, and increased payload loading per particle.
Nanoparticle delivery platform for RNA and DNA therapeutics
A platform for intracellular delivery of RNA and DNA that supports tunable immunogenicity, co-encapsulation of multiple payload types, modular targeting, and increased payload loading per particle.
Services
Platform partnering and collaboration
Collaborative engagements with biopharmaceutical companies to advance development and commercialization of the nanoparticle delivery platform.
Platform partnering and collaboration
Collaborative engagements with biopharmaceutical companies to advance development and commercialization of the nanoparticle delivery platform.
Expertise Areas
- Intracellular delivery of nucleic acids
- Nanoparticle formulation and assembly
- Payload co-encapsulation and combination delivery
- Tissue-targeted delivery using targeting ligands or polymers
Key Technologies
- Nanoparticle delivery platforms
- Modular surface chemistry for particle functionalization
- Co-encapsulation of nucleic acids and biologics
- Targeting ligand conjugation